Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (290)	10/22/2001 12:33:48 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 724

[ off topic ] There's one other that I focus on which you might like for "defensive". KDUS........ Current ask of $0.97, very, very illiquid. Roach Motel like NBSC, and we're coming into sell season for BMY (a shareholder). Market cap of $13 million. No employees, burn almost countered by a tiny flow of license revenue and interest income. Let's say $1.85/share cash, book slightly higher. Potential royalty flow from one of two (not both, first to market if and when) adenosine receptor antagonists. I was using a rate of 4% and estimated 2005 revenues of 16 million. I'm now using 3% and 2006 revenues of 12 million. There is no guidance that I know of. OSIP has recently provided an update re. both projects; one (Solvay/OSIP) is expected in the clinic "imminently", and the other (OSIP) Q1 2002. The indications are congestive heart failure and asthma, respectively. Company owns a variety of other assets (most probably of no value), including a large chunk of Axiom Biotechnologies, a viable company with a very tacky website if you'd like to review...... axiombio.com Carl Icahn is the largest shareholder, and has given no indication whatsoever that a biotech deal is in the cards. Thanks for the lead re. NALGE (AOT). Business should surge?

To: richardred who wrote (290)	10/23/2001 11:35:44 AM
From: tuck	Read Replies (2) \| Respond to of 724

richardred, I apologize for going slightly overboard in describing NBSC's product line. Luckily, Rick sometimes shadows me and cleans up such misconceptions as the idea that they sell centrifuges. I've got to admit it's been a while since I actually looked at their catalog, and I must of have been fantasizing that they munched Fisher Scientific and sold beautiful centrifuges together . . . say, Rick, that would be a good fit in my opinion, though humor aside, clearly it would be FSH doing the munching. Then maybe they could spin out DGI for a handsome profit to some cash-rich genomics company whose lawyers can wade through 300+ page patent apps as part of the DD. Somebody pinch me. Cheers, Tuck